The company targets 120-150 basis points of margin expansion by 2026 as divestitures near completion.
Charles River Laboratories reaffirmed its 2026 earnings per share guidance of $10.80 to $11.30, citing progress on strategic divestitures. The company expects margin expansion of approximately 120-150 basis points as part of its long-term growth plan.
The outlook aligns with prior projections, reflecting confidence in operational efficiency and cost management. Analysts had anticipated the reaffirmation, though some questioned the pace of margin improvement amid macroeconomic pressures.
Shares showed muted reaction in after-hours trading, as investors await further details on divestiture timelines and execution risks.